InvestorsObserver
×
News Home

Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry?

Tuesday, December 22, 2020 10:27 AM | InvestorsObserver Analysts

Mentioned in this article

Is Spero Therapeutics Inc (SPRO) a Winner in the Biotechnology Industry?

Spero Therapeutics Inc (SPRO) is near the top in its industry group according to InvestorsObserver. SPRO gets an overall rating of 73. That means it scores higher than 73 percent of stocks. Spero Therapeutics Inc gets a 88 rank in the Biotechnology industry. Biotechnology is number 29 out of 148 industries.

Overall Score - 73
SPRO has an Overall Score of 73. Find out what this means to you and get the rest of the rankings on SPRO!

What do These Ratings Mean?

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

Our proprietary scoring system captures technical factors, fundamental analysis and the opinions of analysts on Wall Street. This makes InvestorsObserver’s overall rating a great way to get started, regardless of your investing style. Percentile-ranked scores are also easy to understand. A score of 100 is the top and a 0 is the bottom. There’s no need to try to remember what is “good” for a bunch of complicated ratios, just pay attention to which numbers are the highest.

What's Happening With Spero Therapeutics Inc Stock Today?

Spero Therapeutics Inc (SPRO) stock has gained 17.83% while the S&P 500 is down -0.12% as of 10:24 AM on Tuesday, Dec 22. SPRO is up $3.39 from the previous closing price of $19.00 on volume of 235,658 shares. Over the past year the S&P 500 has risen 14.47% while SPRO is up 114.46%. SPRO lost -$4.21 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Spero Therapeutics Inc (SPRO) Stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App